Premium
In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set
Author(s) -
Isola H.,
Kientz D.,
Aleil B.,
Laeuffer P.,
Weil J.,
Wiesel M.L.,
Laforêt M.,
Lin L.,
Mayaudon V.,
Cazenave J.P.
Publication year - 2006
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2005.00723.x
Subject(s) - apheresis , platelet , chemistry , plateletpheresis , lactate dehydrogenase , mean platelet volume , andrology , chromatography , biochemistry , immunology , medicine , enzyme
Pathogen inactivation using the INTERCEPT Blood System™ requires platelet resuspension in InterSol™ and reduced plasma. Platelets in plasma collected on the Haemonetics MCS+® were processed on the INTERCEPT Preparation Set™ for plasma volume reduction and addition of InterSol. The use of the Preparation Set resulted in a mean platelet loss of 5·6 ± 3·4%. Subsequent photochemical treatment (PCT) with amotosalen and ultraviolet A light, and 7 days of storage, resulted in acceptable changes for platelet swirling, lactate, lactate dehydrogenase (LDH), platelet factor‐4 (PF4), p‐selectin, glycoprotein V (GpV), pO 2 , pCO 2 , tumour necrosis factor‐α (TNF‐α) and interleukin‐8 (IL‐8). All platelet units processed with the Preparation Set and PCT met European requirements for leucoreduction and pH values.